+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Malaria Vaccine Market - Global Forecast 2026-2032- Product Image
Malaria Vaccine Market - Global Forecast 2026-2032- Product Image
Sale

Malaria Vaccine Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5313766
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Malaria Vaccine Market is projected to reach USD 373.56 Million in 2026. It is expected to continue growing at a CAGR of 8.79%, reaching USD 623.32 Million by 2032.

The malaria vaccine market is entering a defined scale-up phase as immunization moves from long-running pilot programs into national childhood vaccination schedules. The need is measurable: the World Health Organization reported an estimated 263 million malaria cases and 597,000 deaths in 2023, with children under five in sub-Saharan Africa bearing the highest mortality burden.

Two WHO-recommended malaria vaccines now shape the competitive and public health landscape: RTS,S/AS01 and R21/Matrix-M. Their adoption is expanding the role of vaccine manufacturers, global health funders, national malaria control programs, cold-chain providers, and surveillance partners in an ecosystem that remains closely tied to insecticide-treated nets, seasonal malaria chemoprevention, diagnostics, and antimalarial treatment.

Transformative Shifts in the Malaria Vaccine Landscape

The most important shift is the transition from proof of concept to programmatic delivery. WHO’s 2021 recommendation of RTS,S/AS01 and 2023 recommendation of R21/Matrix-M created a two-vaccine environment, improving procurement flexibility and increasing confidence among endemic countries planning phased malaria vaccine rollouts.

Market dynamics are also changing as demand is driven less by private-pay channels and more by public immunization budgets, Gavi-supported introductions, UNICEF procurement, and ministries of health. Climate variability, insecticide resistance, urban transmission, and population mobility are increasing the importance of integrated malaria prevention strategies, positioning vaccines as a complementary tool rather than a standalone intervention.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the malaria vaccine value chain by accelerating antigen discovery, improving protein-structure modeling, and supporting immune-response analysis across complex parasite life-cycle stages. These capabilities are relevant because Plasmodium falciparum has biological complexity that has historically made vaccine development difficult.

AI is also strengthening operational execution. Predictive analytics can support clinical trial-site selection, adverse-event signal detection, supply planning, and cold-chain optimization in areas where seasonal transmission creates sharp fluctuations in need. For manufacturers and public health agencies, the cumulative impact is faster decision-making, better allocation of limited doses, and more targeted post-introduction surveillance.

Key Regional Insights: Asia-Pacific, Africa, Europe, and the Americas

Africa remains the center of malaria vaccine demand because WHO attributes about 94% of global malaria cases and 95% of malaria deaths to the African region. Routine introductions in countries such as Cameroon and broader Gavi-supported expansion are making the region the primary proving ground for vaccine delivery, safety monitoring, community acceptance, and real-world effectiveness in children.

Asia-Pacific has a mixed profile: India and parts of Southeast Asia continue to manage malaria transmission, while China has achieved WHO malaria-free certification, creating a region that combines disease-control needs with vaccine manufacturing and research capabilities. North America and Europe are primarily innovation, funding, regulatory, and travel-medicine hubs that support malaria vaccine development, evaluation, and global health financing. Latin America’s need is concentrated in Amazon basin transmission pockets, while the Middle East has selective risk areas and procurement relevance through humanitarian and global health financing. Africa remains the largest demand pool, but global participation is distributed across R&D, production, financing, regulation, and implementation.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries face heterogeneous malaria risk, with higher relevance in border, forest, and migrant-worker settings than in highly urbanized markets, making surveillance, targeted immunization planning, and cross-border coordination important. GCC countries are less exposed to domestic malaria burden but remain relevant through travel health, humanitarian assistance, sovereign health investments, and support for disease-control programs in endemic regions.

The European Union and G7 are central to research funding, regulatory science, manufacturing partnerships, and global procurement support for malaria vaccines. BRICS brings together both high-burden and high-capacity markets, notably India’s disease-control and vaccine-production role, China’s elimination experience and manufacturing capacity, and Brazil’s Amazon-focused malaria challenge. NATO is not a malaria market grouping, yet member countries contribute through military medicine, deployment health, outbreak preparedness, and global health security financing that can support vaccine readiness in endemic regions.

Key Country Insights Across Major Malaria Vaccine Markets

The United States and Canada are primarily R&D, donor, travel-medicine, and regulatory markets, while Mexico continues to focus on elimination-oriented surveillance and outbreak prevention. Brazil is the most important listed Latin American country for malaria vaccine relevance because transmission is concentrated in the Amazon region, where access, mobility, and surveillance challenges shape prevention strategies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain contribute through research institutions, development finance, regulatory expertise, vaccine science, and imported malaria management, while Russia has limited endemic-market relevance but retains scientific and regional health capacity. China’s WHO-certified malaria-free status strengthens its role in surveillance, elimination experience, and manufacturing; India remains central due to its malaria burden, national control efforts, and vaccine industry capacity. Japan, Australia, and South Korea contribute through biomedical R&D, financing, regional health-security programs, and partnerships supporting malaria control across Asia-Pacific.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize endemic-country access strategies, including predictable pricing, technology transfer, and supply commitments aligned with national immunization schedules. Manufacturers must design capacity plans around phased rollout, seasonality, country readiness, and procurement cycles rather than conventional commercial demand alone.

Leaders should also invest in pharmacovigilance, implementation research, and combination prevention evidence that demonstrates how malaria vaccines perform alongside insecticide-treated nets, chemoprevention, diagnostics, and case management. Strategic partnerships with global health agencies, immunization financiers, procurement bodies, African ministries of health, and local manufacturers will be essential to building trust, accelerating adoption, and reducing delivery bottlenecks.

Research Methodology

This executive summary is built from verified secondary research and market triangulation using publicly available evidence from WHO malaria reporting, WHO vaccine recommendations, vaccine introduction materials, procurement context from multilateral immunization channels, peer-reviewed vaccine studies, and national malaria control information.

The analysis evaluates epidemiology, policy adoption, product availability, funding pathways, manufacturing capacity, regulatory direction, and regional disease burden. Insights are cross-checked against multiple authoritative sources to avoid unsupported market claims, market sizing, or forecasting, and to ensure that conclusions reflect current malaria vaccine science, public health implementation, and procurement realities.

Conclusion

The malaria vaccine market is no longer theoretical. WHO-recommended products, expanding national introductions, and global financing mechanisms are turning malaria immunization into a practical tool for reducing childhood morbidity and mortality in high-burden settings.

Progress will depend on sustained evidence generation, affordable supply, country readiness, community acceptance, and integration with established malaria control measures. Organizations that combine scientific innovation with equitable access, reliable delivery, and strong surveillance will be best positioned to shape the next phase of malaria vaccine impact.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Malaria Vaccine Market, by Vaccine Type
7.1. Introduction
7.2. Conjugate Vaccine
7.3. Live Attenuated Vaccine
7.4. Mrna Vaccine
7.4.1. Conventional Mrna
7.4.2. Self Amplifying Mrna
7.5. Subunit Vaccine
7.6. Viral Vector Vaccine
7.6.1. Adenovirus Vector
7.6.2. Mva Vector
8. Malaria Vaccine Market, by Age Group
8.1. Introduction
8.2. Adolescent & Adult
8.3. Child
8.3.1. Preschool
8.3.2. School Age
8.4. Infant
9. Malaria Vaccine Market, by Dosage Schedule
9.1. Introduction
9.2. Single Dose
9.3. Three Dose
9.4. Two Dose
10. Malaria Vaccine Market, by End User
10.1. Introduction
10.2. NGOs
10.3. Private Clinics
10.4. Public Immunization Programs
10.4.1. Local Programs
10.4.2. National Programs
11. Malaria Vaccine Market, by Route Of Administration
11.1. Introduction
11.2. Intramuscular
11.3. Oral
11.4. Subcutaneous
12. Malaria Vaccine Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Malaria Vaccine Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Malaria Vaccine Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AstraZeneca plc
16.2. Bharat Biotech International Limited
16.3. BioNTech SE
16.4. Emergent BioSolutions Inc.
16.5. GSK plc
16.6. Instituto Butantan
16.7. Johnson & Johnson
16.8. Merck & Co., Inc.
16.9. Moderna, Inc.
16.10. Novavax, Inc.
16.11. PathWest Laboratory Medicine WA
16.12. Pfizer Inc.
16.13. Sanofi S.A.
16.14. Serum Institute of India Private Limited
16.15. Takeda Pharmaceutical Company Limited
16.16. Valneva SE
List of Figures
FIGURE 1. GLOBAL MALARIA VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MALARIA VACCINE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MALARIA VACCINE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MALARIA VACCINE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MALARIA VACCINE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MALARIA VACCINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL MALARIA VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL MALARIA VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL LIVE ATTENUATED VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MRNA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MRNA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MRNA VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CONVENTIONAL MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL SELF AMPLIFYING MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL SELF AMPLIFYING MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL SELF AMPLIFYING MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SUBUNIT VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL VIRAL VECTOR VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ADENOVIRUS VECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ADENOVIRUS VECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ADENOVIRUS VECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL MVA VECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL MVA VECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL MVA VECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ADOLESCENT & ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ADOLESCENT & ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ADOLESCENT & ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CHILD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CHILD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CHILD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PRESCHOOL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PRESCHOOL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PRESCHOOL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SCHOOL AGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SCHOOL AGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SCHOOL AGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INFANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INFANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INFANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SINGLE DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SINGLE DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SINGLE DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL THREE DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL THREE DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL THREE DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL TWO DOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TWO DOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TWO DOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL NGOS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL NGOS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL NGOS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PRIVATE CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PRIVATE CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PRIVATE CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PUBLIC IMMUNIZATION PROGRAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL PUBLIC IMMUNIZATION PROGRAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL PUBLIC IMMUNIZATION PROGRAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL LOCAL PROGRAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL LOCAL PROGRAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL LOCAL PROGRAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL NATIONAL PROGRAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL NATIONAL PROGRAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL NATIONAL PROGRAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 88. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 89. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 114. EUROPE MALARIA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. EUROPE MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 116. EUROPE MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 117. EUROPE MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 118. EUROPE MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 119. EUROPE MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 120. EUROPE MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 121. EUROPE MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. EUROPE MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 123. EUROPE MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 134. AFRICA MALARIA VACCINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 136. AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 137. AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 138. AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 139. AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 140. AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 141. AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 143. AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. ASEAN MALARIA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. ASEAN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 147. ASEAN MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 148. ASEAN MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 149. ASEAN MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 150. ASEAN MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 151. ASEAN MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 152. ASEAN MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 153. ASEAN MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 154. ASEAN MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 155. GCC MALARIA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. GCC MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 157. GCC MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 158. GCC MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 159. GCC MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 160. GCC MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 161. GCC MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 162. GCC MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. GCC MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 164. GCC MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 175. BRICS MALARIA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 176. BRICS MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 177. BRICS MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 178. BRICS MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 179. BRICS MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 180. BRICS MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 181. BRICS MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 182. BRICS MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. BRICS MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 184. BRICS MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. G7 MALARIA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. G7 MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 187. G7 MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 188. G7 MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 189. G7 MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 190. G7 MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 191. G7 MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 192. G7 MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. G7 MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 194. G7 MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 195. NATO MALARIA VACCINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 196. NATO MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 197. NATO MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 198. NATO MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 199. NATO MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 200. NATO MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 201. NATO MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 202. NATO MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. NATO MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 204. NATO MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 205. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 212. UNITED STATES MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 213. UNITED STATES MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. UNITED STATES MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 215. UNITED STATES MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 216. CANADA MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. CANADA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 218. CANADA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 219. CANADA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 220. CANADA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 221. CANADA MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 222. CANADA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 223. CANADA MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 224. CANADA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 225. CANADA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 226. MEXICO MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 227. MEXICO MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 228. MEXICO MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 229. MEXICO MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 230. MEXICO MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 231. MEXICO MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 232. MEXICO MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 233. MEXICO MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. MEXICO MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 235. MEXICO MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 236. BRAZIL MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. BRAZIL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 238. BRAZIL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 239. BRAZIL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 240. BRAZIL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 241. BRAZIL MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 242. BRAZIL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 243. BRAZIL MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 244. BRAZIL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 245. BRAZIL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 253. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 256. GERMANY MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. GERMANY MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 258. GERMANY MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 259. GERMANY MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 260. GERMANY MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 261. GERMANY MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 262. GERMANY MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 263. GERMANY MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. GERMANY MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 265. GERMANY MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 266. FRANCE MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 267. FRANCE MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 268. FRANCE MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 269. FRANCE MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 270. FRANCE MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 271. FRANCE MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 272. FRANCE MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 273. FRANCE MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. FRANCE MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 275. FRANCE MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 276. RUSSIA MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. RUSSIA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 278. RUSSIA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 279. RUSSIA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 280. RUSSIA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 281. RUSSIA MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 282. RUSSIA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 283. RUSSIA MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. RUSSIA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 286. ITALY MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 287. ITALY MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 288. ITALY MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 289. ITALY MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 290. ITALY MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 291. ITALY MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 292. ITALY MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 293. ITALY MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. ITALY MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 295. ITALY MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. SPAIN MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 297. SPAIN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 298. SPAIN MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 299. SPAIN MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 300. SPAIN MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 301. SPAIN MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 302. SPAIN MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 303. SPAIN MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. SPAIN MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 305. SPAIN MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 306. CHINA MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. CHINA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 308. CHINA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 309. CHINA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 310. CHINA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 311. CHINA MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 312. CHINA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 313. CHINA MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 314. CHINA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 315. CHINA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 316. INDIA MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 317. INDIA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 318. INDIA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 319. INDIA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 320. INDIA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 321. INDIA MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 322. INDIA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 323. INDIA MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 324. INDIA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 325. INDIA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 326. JAPAN MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. JAPAN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 328. JAPAN MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 329. JAPAN MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 330. JAPAN MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 331. JAPAN MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 332. JAPAN MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 333. JAPAN MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. JAPAN MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 335. JAPAN MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 336. AUSTRALIA MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 337. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 338. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 339. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 340. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 341. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 342. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 343. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 345. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 346. SOUTH KOREA MALARIA VACCINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 347. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 348. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2017-2032 (USD MILLION)
TABLE 349. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2017-2032 (USD MILLION)
TABLE 350. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 351. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY CHILD, 2017-2032 (USD MILLION)
TABLE 352. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2017-2032 (USD MILLION)
TABLE 353. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 354. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2017-2032 (USD MILLION)
TABLE 355. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 356. GLOBAL MALARIA VACCINE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 357. GLOBAL MALARIA VACCINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • AstraZeneca plc
  • Bharat Biotech International Limited
  • BioNTech SE
  • Emergent BioSolutions Inc.
  • GSK plc
  • Instituto Butantan
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • PathWest Laboratory Medicine WA
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Private Limited
  • Takeda Pharmaceutical Company Limited
  • Valneva SE

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 373.56 Million
Forecasted Market Value ( USD ) by 2032 $ 623.32 Million
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Malaria Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Malaria Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Malaria Vaccines Market - Global Strategic Business Report - Product Image

Malaria Vaccines Market - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From
Malaria Vaccines Market Report 2026 - Product Image

Malaria Vaccines Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Vaccines Market - Global Forecast 2026-2032 - Product Image

Vaccines Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Infectious Vaccines Market - Global Forecast 2026-2032 - Product Image

Infectious Vaccines Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From

About the Malaria Vaccine Market

The Malaria Vaccine market is a subset of the larger Vaccines market. It is focused on the development and distribution of vaccines to prevent and treat malaria, a mosquito-borne infectious disease that affects millions of people worldwide. Vaccines are the most effective way to prevent malaria, and the market is driven by the need to reduce the burden of the disease. The Malaria Vaccine market is composed of a variety of stakeholders, including pharmaceutical companies, research institutions, and public health organizations. These stakeholders collaborate to develop and distribute vaccines to those in need. Vaccines are typically administered through injection or oral administration, and are often combined with other preventative measures such as insecticide-treated bed nets and indoor residual spraying. The Malaria Vaccine market is highly competitive, with a number of companies vying for market share. Some of the major players in the market include GlaxoSmithKline, Sanofi, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.